


Stabilis



Methotrexate sodium



Noms commerciaux

Abitrexate	Afrique du sud
Antifolan	Roumanie
Artrait	Argentine
Bendatrexat	Allemagne
Biometrox	Brésil
Ebetrex	Suisse
Ebetrexate	Autriche
Emthexat	Turquie
Emthexate	Afrique du sud, Belgique, Espagne, Pays bas
Ledertrexate	Belgique, France, Luxembourg, Maroc
Maxtrex	Grande Bretagne
Metex	Allemagne, Norvège
Methoblastin	Afrique du sud
Methotrexamed	Allemagne
Methotrexate	France
Metobject	Chili, Danemark, Espagne, Finlande, France, Grande Bretagne, Pays bas, Suède, Suisse
Metotrexato	Chili
Trexan	Finlande
Trexat	Allemagne



Stabilité des solutions

		0,36 mg/ml	23°C		72			1501
		0,36 mg/ml	4°C		72			1501
		1,25 & 12,5 mg/ml	2-8°C		105			110
		2,5 mg/ml	25°C		7			739
	RL	2,5 mg/ml	25°C		7			739
	E B	2 mg/ml	23°C		48			31
	E B	2 mg/ml	4°C		48			31
	E B	2,5 mg/ml	25°C		7			739

PVC		0,225 mg/ml	4°C		30			162
PVC		0,36 mg/ml	23°C		72			1501
PVC		0,36 mg/ml	4°C		72			1501
PVC		0,5 mg/ml	-20°C		30			859
PVC		24 mg/ml	4°C		30			162
PVC		0,1 & 1 & 20 mg/ml	-20°C		84			1021
PVC		1,25 & 12,5 mg/ml	2-8°C		105			110
PE		0,36 mg/ml	21°C-22°C		48			1520
PE		0,36 mg/ml	23°C		72			1501
PE		0,36 mg/ml	4°C		72			1501
PE		0,36 mg/ml	4°C		48			1520
POF		0,2 mg/ml	23-27°C		28			3980
POF		20 mg/ml	23-27°C		28			3980
POF		0,2 mg/ml	23-27°C		3			3980
POF		20 mg/ml	23-27°C		28			3980
PE		50 mg/ml	25°C		70			1155
PE	EI B	2 mg/ml	23°C		48			31
PE	EI B	2 mg/ml	4°C		48			31
PE	Ø	2,5 mg/ml	25°C		7			1469
PE	Ø	2,5 mg/ml	4°C		7			1469
PE	Ø	25 mg/ml	2-8°C		84			3670
PE	Ø	25 & 100 mg/ml	2-8°C		14			4578
PE	Ø	25 & 100 mg/ml	21°C		14			4578



Stabilité en mélange

		6,25 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
	EI B	0,0279 mg/ml	23°C		Cytarabine : 0,442 mg/ml	48		1661
	EI B	0,0314 mg/ml	23°C		Cytarabine : 0,484 mg/ml Hydrocortisone sodium succinate : 0,478 mg/ml	48		1661
	EI B	0,0581 mg/ml	23°C		Cytarabine : 0,477 mg/ml Hydrocortisone sodium succinate : 0,467 mg/ml	48		1661
	EI B	0,0542 mg/ml	23°C		Cytarabine : 0,433 mg/ml	48		1661

	EI B	0,0721 mg/ml	23°C	?	Cytarabine : 0,479 mg/ml Hydrocortisone sodium succinate : 0,489 mg/ml	48	✓	1661
	EI B	0,0649 mg/ml	23°C	?	Cytarabine : 0,431 mg/ml	48	✓	1661
	EI B	0,0314 mg/ml	4°C	?	Cytarabine : 0,484 mg/ml Hydrocortisone sodium succinate : 0,478 mg/ml	48	✓	1661
	EI B	0,0279 mg/ml	4°C	?	Cytarabine : 0,442 mg/ml	48	✓	1661
	EI B	0,0581 mg/ml	4°C	?	Cytarabine : 0,477 mg/ml Hydrocortisone sodium succinate : 0,467 mg/ml	48	✓	1661
	EI B	0,0542 mg/ml	4°C	?	Cytarabine : 0,433 mg/ml	48	✓	1661
	EI B	0,0721 mg/ml	4°C	?	Cytarabine : 0,479 mg/ml Hydrocortisone sodium succinate : 0,489 mg/ml	48	✓	1661
	EI B	0,0649 mg/ml	4°C	?	Cytarabine : 0,431 mg/ml	48	✓	1661
		0,5 & 6 mg/ml	21°C-23°C		Ondansetron hydrochloride : 0,03 & 0,3 mg/ml	48	✓	184
		1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Cytarabine : 4,1 mg/ml	24	✓	1028
		5,3 mg/ml	24-26°C		Methylprednisolone sodium succinate : 0,8 mg/ml	48	✓	4641
		3 mg/ml	24-26°C		Methylprednisolone sodium succinate : 0,5 mg/ml	48	✓	4641
		3 mg/ml	24-26°C		Hydrocortisone sodium succinate : 2,5 mg/ml	24	✓	4641
		6 mg/ml	24-26°C		Hydrocortisone sodium succinate : 4 mg/ml	24	✓	4641
	RL	1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Cytarabine : 4,1 mg/ml	24	✓	1028
	EI B	1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Cytarabine : 4,1 mg/ml	24	✓	1028
	∅	1,54 mg/ml	5°C		Methylprednisolone sodium succinate : 0,51 mg/ml Cytarabine : 3,85 mg/ml	12	✓	3275



Facteur influençant la stabilité

		→		1155 1158 3731
	[1 mg/ml]	→		145
		→		301



Compatibilités

			301
			4154
			1415

	Methotrexate sodium : 15 mg/ml Allopurinol sodium : 3 mg/ml		307
	Methotrexate sodium : 15 mg/ml Amifostine : 10 mg/ml		3
	Methotrexate sodium : 15 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Methotrexate sodium : 30 mg/ml Asparaginase : 120 UI/ml		150
	Methotrexate sodium : 15 mg/ml Aztreonam : 40 mg/ml		99
	Methotrexate sodium : 0.4 mg/ml Cefalotin sodium : 1 mg/ml		431
	Methotrexate sodium : 30 mg/ml Ceftriaxone disodium : 100 mg/ml		150
	Methotrexate sodium Chlorpromazine hydrochloride		3637
	Methotrexate sodium : 30 mg/ml Cyclophosphamide : 20 mg/ml		150
	Methotrexate sodium Cytarabine		3580
	Methotrexate sodium : 0.2 mg/ml Cytarabine : 0.4 mg/ml		431
	Methotrexate sodium Cytarabine		3637
	Methotrexate sodium : 30 mg/ml Cytarabine : 0.6 mg/ml		150
	Methotrexate sodium Cytarabine	RL	978
	Methotrexate sodium : 30 mg/ml Daunorubicin hydrochloride : 0.52 mg/ml		150
	Methotrexate sodium : 30 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		150
	Methotrexate sodium : 12,5 mg/ml Doripenem : 5 mg/ml		2262
	Methotrexate sodium : 25 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
	Methotrexate sodium : 30 mg/ml Doxorubicin hydrochloride : 0.4 mg/ml		150
	Methotrexate sodium : 15 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Methotrexate sodium : 25 mg/ml Droperidol : 2.5 mg/ml		1088
	Methotrexate sodium Droperidol		3637
	Methotrexate sodium : 25 mg/ml Droperidol : 2,5 mg/ml		763
	Methotrexate sodium : 30 mg/ml Etoposide : 0.6 mg/ml		150
	Methotrexate sodium : 15 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Methotrexate sodium : 15 mg/ml Filgrastim : 30 µg/ml		244

		Methotrexate sodium Fludarabine phosphate		3637
		Methotrexate sodium : 15 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Methotrexate sodium : 25 mg/ml Fluorouracil : 50 mg/ml		763
		Methotrexate sodium : 0.2 mg/ml Fluorouracil : 0.25 mg/ml		431
		Methotrexate sodium Fluorouracil		3637
		Methotrexate sodium Fluorouracil		3474
		Methotrexate sodium : 30 mg/ml Folinate calcium : 10 mg/ml		150
		Methotrexate sodium : 25 mg/ml Folinate calcium : 10 mg/ml		763
		Methotrexate sodium : 25 mg/ml Furosemide : 10 mg/ml		763
		Methotrexate sodium : 25 mg/ml Furosemide : 10 mg/ml		1088
		Methotrexate sodium : 25 mg/ml Gallium nitrate : 1 mg/ml		91
		Methotrexate sodium : 15 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Methotrexate sodium : 12.5 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Methotrexate sodium Heparin sodium		3637
		Methotrexate sodium : 25 mg/ml Heparin sodium : 1000 UI/ml		763
		Methotrexate sodium : 30 mg/ml Heparin sodium : 500 UI/ml		150
		Methotrexate sodium : 1 & 3 mg/ml Hydroxyzine dihydrochloride : 0.5 mg/ml		331
		Methotrexate sodium Idarubicin hydrochloride		3637
		Methotrexate sodium : 25 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Methotrexate sodium : 30 mg/ml Ifosfamide : 36 mg/ml		150
		Methotrexate sodium : 15 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Methotrexate sodium : 15 mg/ml Linezolid : 2 mg/ml		1925
		Methotrexate sodium : 15 mg/ml Melphalan : 0.1 mg/ml		169
		Methotrexate sodium : 30 mg/ml Mesna : 1.8 mg/ml		150
		Methotrexate sodium : 25 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Methotrexate sodium Metoclopramide hydrochloride		3637

		Methotrexate sodium : 30 mg/ml Midazolam hydrochloride : 5 mg/ml		150
		Methotrexate sodium : 30 mg/ml Nalbuphine hydrochloride : 10 mg/ml		150
		Methotrexate sodium : 15 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Methotrexate sodium : 0,5 mg/ml Ondansetron hydrochloride : 0,03 mg/ml		184
		Methotrexate sodium : 0,5 mg/ml Ondansetron hydrochloride : 0,3 mg/ml		184
		Methotrexate sodium : 6 mg/ml Ondansetron hydrochloride : 0,3 mg/ml		184
		Methotrexate sodium : 6 mg/ml Ondansetron hydrochloride : 0,03 mg/ml		184
		Methotrexate sodium : 30 mg/ml Ondansetron hydrochloride : 2 mg/ml		150
		Methotrexate sodium : 30 mg/ml Oxacillin sodium : 250 mg/ml		150
		Methotrexate sodium : 12,5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Methotrexate sodium : 15 mg/ml Paclitaxel : 1.2 mg/ml		85
		Methotrexate sodium : 30 mg/ml Paracetamol : 200 mg/ml		150
		Methotrexate sodium : 15 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Methotrexate sodium Promethazine hydrochloride		3637
		Methotrexate sodium : 15 mg/ml Propofol : 10 mg/ml		300
		Methotrexate sodium Ranitidine hydrochloride		3637
		Methotrexate sodium : 15 mg/ml Sargramostim : 10 µg/ml		335
		Methotrexate sodium : 15 mg/ml Teniposide : 0.1 mg/ml		905
		Methotrexate sodium : 15 mg/ml Thiotepa : 1 mg/ml		249
		Methotrexate sodium : 30 mg/ml Vancomycin hydrochloride : 5 mg/ml		150
		Methotrexate sodium : 25 mg/ml Vinblastine sulfate : 1 mg/ml		763
		Methotrexate sodium : 0.008 mg/ml Vincristine sulfate : 0.004 mg/ml		431
		Methotrexate sodium : 30 mg/ml Vincristine sulfate : 0.1 mg/ml		150
		Methotrexate sodium : 25 mg/ml Vincristine sulfate : 1 mg/ml		763
		Methotrexate sodium : 30 mg/ml Vindesine sulfate : 0.1 mg/ml		150
		Methotrexate sodium : 15 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31	Revue	Zhang Y, Xu QA, Trissel LA, Gilbert DL. Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott's B solution. Hosp Pharm 1996 ; 31: 965-970.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110	Revue	Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 1989 ; 54: 181-189.
145	Revue	Lorillon P, Corbel JC, Mordelet MF, Basle B, Guesnier LR. Photosensibility of 5-fluorouracil and methotrexate in translucent or opaque perfusers. J Pharm Clin 1992 ; 11: 285-295.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
162	Revue	Benaji B, Dine T, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Gressier B, Cazin M, Cazin JC. Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures. Int J Pharm 1994 ; 105: 83-87.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.



































184	Revue	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplastic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Revue	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplastic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
431	Revue	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
739	Revue	Cradock JC, Kleinmann LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm 1978 ; 35: 402-406.
763	Revue	Cohen MH, Johnson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
859	Revue	Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ. Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment. Nor Pharm Acta 1983 ; 45: 61-67.

905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
978	Revue	Dick DM, Woloschuk DMM. Methotrexate and cytarabine for intrathecal administration. Can J Hosp Pharm 1994 ; 47: 147.
1021	Revue	Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J. Methotrexate in solutions - A stability test for the hospital pharmacy. J Clin Hosp Pharm 1986 ; 11: 343-348.
1028	Revue	Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm 1984 ; 41: 1802-1806.
1088	Revue	Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH. Drug trapping in intravenous infusion side arms. JAMA 1984 ; 252: 2392.
1155	Revue	Wright MP, Newton JM. Stability of methotrexate injection in prefilled plastic disposable syringes. Int J Pharm 1988 ; 45: 237-244.
1158	Revue	McElnay JC, Elliott DS, Cartwright-Shamoon J, D'Arcy PF. Stability of methotrexate and vinblastine in burette administration sets. Int J Pharm 1988 ; 47: 239-247.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1469	Revue	Jacolot A, Arnaud P, Lecompte D, Alamercery S, Caroff E, Naveau C, Guillot T, Bousselet M, Brion F. Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days. Int J Pharm 1996 ; 128: 283-286.
1501	Revue	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratoire	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1661	Revue	Trissel LA, King KM, Zhang Y, Wood AM. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott's B Solution for intrathecal use. J Oncol Pharm Practice 2002 ; 8: 27-32.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.

1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3275	Revue	D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate Am J Health-Syst Pharm 2012 ; 69: 232-240.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics HameIn Pharmaceuticals 2014
3670	Revue	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3731	Revue	Chatterji D.C, Gallelli J.F. Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci 1978 ; 67, 4: 526-530.
3980	Revue	Nissen K.B, Jorgensen L.B, Berg D.L, Andersen G. Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities. Am J Health-Syst Pharm 2017 ; 74,9: e211-e223
4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4578	Thèse	Respaud R. Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques 2011
4641	Revue	Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P. Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies. Eur J Pharm Sci 2021 ;167: 106039.



Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% ou glucose 5%	 A l'abri de la lumière
 Heure	 Chlorure de sodium 0,9%
 Jour	 Lumière
RL Ringer lactate	El B Solution d'Elliott B
 Non précisée	 Polyvinyl chlorure
 Polyéthylène	 Polyoléfine
 Glucose 5%	 Seringue polypropylène
 Eau pour préparation injectable	 Aucun
 Stabilité en mélange	 Solvant
 Molécule	 Facteur influençant la stabilité
 Provoque	 Dégradation
 Nutrition parentérale (mélange binaire)	 Compatibilités
 Précipitation immédiate	 Incompatible
 Incompatibilité non précisée	 Compatible
 Nutrition parentérale (mélange ternaire)	 Instabilité chimique
 Précipitation en 1 heure	 Changement de couleur à 4 heures
 Changement de couleur	 Précipitation en 2 heures
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Perfusion continue
 Intramusculaire	 Sous cutanée
 Intraartérielle	 Intrathécale
 Perfusion SC continue	 Bibliographie
 Dictionnaire	